|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/40 | |
| A61P 3/06 | |||
| A61K 39/395 | |||
| A61K 39/00 |
| (11) | Number of the document | 2756004 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12761864.3 |
| Date of filing the European patent application | 2012-09-12 | |
| (97) | Date of publication of the European application | 2014-07-23 |
| (45) | Date of publication and mention of the grant of the patent | 2019-12-25 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2012/054756 |
| Date | 2012-09-12 |
| (87) | Number | WO 2013/039969 |
| Date | 2013-03-21 |
| (30) | Number | Date | Country code |
| 201161535392 P | 2011-09-16 | US | |
| 201161559162 P | 2011-11-14 | US | |
| 201261641321 P | 2012-05-02 | US |
| (72) |
SWERGOLD, Gary, US
|
| (73) |
Regeneron Pharmaceuticals, Inc.,
777 Old Saw Mill River Road, Tarrytown, NY 10591,
US
|
| (54) | INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS |
| INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS |